methods) are annotated (gray). Distribution of peptides presented uniquely by tumor
organoid clones reveals many tumor-speciﬁc ligands with high afﬁnity. d Length distribution of peptide ligands from normal (N), tumor (T), and unique
tumor (T unique). Peptide ligands unique to CRC tumor organoids appear to be spread over a broader length distribution. Ligand characteristics for each
individual tumor organoid clone are shown in Figs. S1 and S2. Plotting data tabulated in Source Data.

Therefore, this implies that one CRC organoid clone may present could subsequently survey the proteome and ligandome heteroan HLA peptide ligand strongly, whereas another clone only geneity between individual clones largely without considering
weakly. We further veriﬁed that these intensity differences were clone-speciﬁc genetic and protein-coding changes, to focus on
not of technical nature, given that biological replicates of HLA studying the fundamental logic in cell-surface presentation. Since
ligandomes measured months apart did not vary by more than the proteome and ligandome are paired to each clone, steady-
1%. We believe such clone-to-clone variation in HLA peptide state protein abundance and HLA class I peptide ligand preligand presentation should be critically considered, especially in sentation could easily be correlated. Amplifying single cells using
targeting residual disease after immunotherapy. organoid technology also enables clone-speciﬁc proteome and
 ligandome signatures to be detected without signal averaging,
Discussion unlike most of the tissue-based analyses reported to date. We
HLA class I peptide ligands presented abundantly, exclusively, believe our approach also adds sensitivity to identify a ligandome
and uniformly on the tumor surface provide ideal starting points much larger than previously possible from patient-derived
to design personalized immunotherapy. In this work, we modeled biopsies46,47.
single-cell level heterogeneity in CRC from single cells using Comparing between clonal proteomes of organoid-expanded
patient-derived clonal organoids, and correlated clonal tumor tumor cells against normal colon organoids of the same patient,
proteomes with their respective HLA ligandomes. we observed that established cancer hallmarks were well-retained
 The strategy presented here has various advantages. The three- in every tumor organoid line, whereas these speciﬁc features were
dimensional spatial signaling in organoid culture recapitulates the not present and also not acquired by the normal colon organoids
gut (patho-)physiology more accurately than ﬂat in vitro expan- during expansion, further verifying the validity of our experisions. Parallel analysis of normal colon organoids from the same mental model. Whilst functional ontology of many proteome
patient allowed us to directly assess speciﬁcity of proteome and differences was conserved between tumor clones (e.g. mTOR),
ligandome signatures to CRC cells, in largely the same patient heterogeneity still exists in redundant pathways of epigenetic
genetic background. In the background of low mutation load, we regulation and chromatin remodeling (e.g. KMTs and KATs).

 a MUC2 VIWDKRTTV FLDEKGRCV
 b DACH1 KMVDLRGAKV
 40
 Normalized abundance

 40

 Normalized abundance
 38 1.5 × 105 Exp. 1 7.5 × 105 Exp. 1 6 × 105
 38 Exp. 1
 36 Exp. 2 Exp. 2 36 Exp. 2
 34 1 × 106 5 × 105 34 4 × 105

 Intensity
 (Log2)

 Intensity

 Intensity
 (Log2)
 32 Not detected 32 Not detected
 30 30
 28 5 × 105 2.5 × 105 28 2 × 105
 26 26
 24 24
 22 0 0 22 0
 N T1 T3 T4 T5 N T1 T3 T4 T5 N T1 T3 T4 T5 N T1 T3 T4 T5 N T1 T3 T4 T5

 c
 DNA damage sensors DNA damage repair proteins
 ATR PRKDC RAD51 BCR BRCA1 BRCA2
 32 40 32 32 32 32
 Normalized abundance

 Normalized abundance
 Normalized abundance

 Normalized abundance

 Normalized abundance
 Normalized abundance
 ns
 31 ns 39 31 31 31 31
 30 38 30 ns 30 30 30
 29 ns 37 29 29 29 29
 (Log2)

 (Log2)
 36 28
 (Log2)

 (Log2)

 (Log2)
 (Log2)
 28 28 28 28
 27 35 27 27 27 27
 26 34 26 26 26 26
 25 33 25 25 25 25
 24 32 24 24 24 24
 23 31 23 23 23 23
 22 30 22 22 22 22
 N T1 T3 T4 T5 N T1 T3 T4 T5 N T1 T3 T4 T5 N T1 T3 T4 T5 N T1 T3 T4 T5 N T1 T3 T4 T5

 KVDSMVSTV FLDVFLPRV RLADEFGVAV GMMEGEGKGPLL KMLNEHDFEV ILESSLHKV
 4 × 105 Exp. 1 8 × 105 Exp. 1
 6 × 106 Exp. 1 6 × 105 Exp. 1
 8 × 105 Exp. 1 4 × 105 Exp. 1
 Exp. 2 Exp. 2 Exp. 2 Exp. 2 Exp. 2 Exp. 2
 3 × 105 6 × 105 4.5 × 106 4.5 × 105 6 × 105 3 × 105
 Intensity
 Intensity

 Intensity
 Intensity

 Intensity
 Intensity

 2 × 105 4 × 105 3 × 106 3 × 105 4 × 105 2 × 105

 1 × 105 2 × 105 1.5 × 106 1.5 × 105 2 × 105 1 × 105

 0 0 0 0 0 0
 N T1 T3 T4 T5 N T1 T3 T4 T5 N T1 T3 T4 T5 N T1 T3 T4 T5 N T1 T3 T4 T5 N T1 T3 T4 T5

deep proteome analysis (left), but two HLA peptide ligands derived from MUC2 degradation were predominantly presented by all CRC tumor organoid
clones (right). For each peptide, normalized peptide intensities were summed from three replicated measurements by HCD (Exp1), or EThcD (Exp2),
respectively. b The DACH1 protein was similarly not detected in the deep proteome analysis (left), but consistently presented on all tumor organoid clones,
and consistently detected in both HCD and EThcD MS fragmentation methods. c Peptides derived from degradation of DNA damage sensors and repair
proteins were prominently presented by CRC organoid clones as HLA peptides. Signiﬁcant changes in protein abundance with respect to normal colon
organoids were determined based on three technical replicates with a two-sided student’s t test: *p < 0.05; **p < 0.01. Data presented as mean values ±
standard deviation. Plotting data tabulated in Source Data.

 a T3 T4 b

 MST1R TP53 TRAF2
 ns ns
 32 32 32
 Normalized abundance

 Normalized abundance

 Normalized abundance
 ns
 0 0 31 31 ns 31 ns
 30 ns
 30 30 ns
 29 ns
 29 29
 (Log2)

 28
 (Log2)

 (Log2)
 28 28
 27 27 27
 26 26 26
 25 25 25
 24 24 24
 5 23 23 23
 1 2 22
 22 22
 0 17
 N T1 T3 T4 T5 N T1 T3 T4 T5 N T1 T3 T4 T5

 GTMDGRILQV GLAPPQHLIRV AMADLEQKV
 6 20 3 × 106 Exp. 1
 9 × 105 Exp. 1 1.5 × 106 Exp. 1
 Exp. 2 Exp. 2 Exp. 2

 2 × 106 6 × 105 1 × 106
 Intensity
 Intensity

 Intensity

 T1 T5
 121
 1 × 106 3 × 105 5 × 106
 0 9
 16 12
 0 0 0
 N T1 T3 T4 T5 N T1 T3 T4 T5 N T1 T3 T4 T5
 9

by either HCD (Exp 1) or EThcD (Exp 2) fragmentation. Most ligands not detected on normal colon organoids were shared by at least three tumor clones,
except for 17 ligands unique to T5 only. b Protein abundance and peptide ligand abundance for MST1R, TP53, and TRAF2 from all organoid lines. Even
though protein levels of MST1R, TRAF2, and TP53 were not signiﬁcantly different between the four CRC tumor organoid lines, presentation of peptide
ligands appear to be speciﬁc to only T5. Signiﬁcant changes in protein abundance were determined with respect to normal colon organoids based on three
technical replicates with a two-sided student’s t test: *p < 0.05; **p < 0.01. Data presented as mean values ± standard deviation. Plotting data tabulated in
Source Data.

These observations also mirror the selective pressure in vivo, up to 97% of ligandome overlap even with normal colon orgawhich evolves single cancer cells via multiple routes towards the noids. This enlightens on the perennial challenges in neo-antigen
same signaling outcome48. discovery49,50, where even in the context of a mutation-rich
 More intriguingly, despite clear clustering of CRC organoid cancer, a large proportion of the tumor-surface HLA molecules is
proteomes away from normal colon organoids, we observed that still occupied by peptides derived from routine protein turnover.
these protein-level changes are qualitatively buffered at the level More recently, neo-antigen discovery from non-coding regions
of HLA peptide ligand presentation, such that tumor clones share have been attempted involving proteogenomics approaches and

ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-19142-9

 100 < 2-fold Methods
 90 > 2-fold Human material and informed consent. The organoid lines used in this study
 80 were derived from biopsies (provided by Departments of Surgery and Pathology of
 the Diakonessenhuis hospital, Utrecht, The Netherlands) of a CRC and adjacent
 % Peptides 70 healthy colon mucosal epithelium taken from colon tissue resected during a left
 60 hemicolectomy to remove a CRC from a female patient (71 years of age). Tissue
 50 collection was approved by the medical ethical committee (METC) of the Diako-
 40 nessenhuis hospital, in agreement with the declaration of Helsinki and according to
 Dutch and European Union legislation. The samples were collected under METC
 30
 protocol 12/093 HUB-Cancer following written informed consent at the Diako-
 20 nessenhuis hospital Utrecht.
 10
 0 Organoid generation and cultures. Colonic epithelial organoid lines were derived
 as previously described56,57. Brieﬂy, crypts of the healthy portion of the colonic
 3

 4

 T3 4
 5
 5

 JY 5
 Y
 :T

 :T

 :T
 :T
 :T

 :T
 :J
 epithelium (at least 10 cm away from the tumor side) were isolated by digestion of
 T1

 T1

 T3
 T1

 T4
 the intestinal mucosa in chelation solution (5.6 mM Na2HPO4, 8.0 mM KH2PO4,
 supplemented with dithiotreitol (0.5 mM, Sigma) and EDTA (2 mM, in-house) for
ligand intensities from each tumor organoid clone were compared by
 30 min at 4 °C. Colonic crypts were subsequently plated in basement membrane
retention time alignment and label-free quantiﬁcation in a pair-wise extract (BME; Cultrex PC BME RGF type 2, Amsbio). Organoids were grown in
manner. Between 15–25% of all ligands varied in intensity by more than 2- human intestinal stem cell medium (HISCM), which is composed of Advanced
fold in each pairwise comparison (black). Quantitative variations by more Dulbecco’s modiﬁed Eagle medium/F12 supplemented with penicillin/streptomythan 2-fold were extremely few at <1%, between two independent cin, 10 mM HEPES and Glutamax (all Gibco, Thermo Fischer Scientiﬁc) with 50%
 Wnt3a conditioned medium (in-house), 20% R-Spondin1 conditioned medium
preparations of JY cell line peptide ligands analyzed months apart with the (in-house), 10% Noggin conditioned medium (in-house), 1x B27, 1.25mM N-acetyl
same LC-MS settings, validating these quantitative ligand variations cysteine, 10 mM nicotinamide, 50 ng/ml human EGF, 10 nM Gastrin, 500 nM A83observed between tumor organoid clones were not of technical nature. 01, 3 µM SB202190, 10 nM prostaglandine E2 and 100 µg/ml Primocin (Invivogen).
Plotting data tabulated in Source Data. Tumor biopsies were digested into single cells using collagenase II (1 mg/ml, Gibco,
 Thermo Fischer Scientiﬁc), supplemented with hyaluronidase (10 µg/ml) and
 LY27632 (10 µM) for 30 min at 37 °C while shaking. Dissociated tumor cells were
 plated in BME and organoids were cultured in HICS minus Wnt conditioned
large computational efforts51,52. While these pipelines are medium and supplemented with 10 µM LY27632 at 37 °C.
streamlined to pick up the rare tumor-speciﬁc mutated antigen
events, these approaches do not focus enough, during data ana- Clonal organoid derivation and ampliﬁcation. To generate clonal tumor orga-
 noid lines, early passage tumor organoids were dissociated into single cells by
lysis, on wild type ligands that are still over-presented from TryPLE express (Thermo Fischer Scientiﬁc), washed and suspended in FACS buffer
altered proteasome degradation and functional processing. (PBS with 2 mM ETDA and 5% FCS). Prior to FACS puriﬁcation, DAPI was added
 We propose, on the other hand, that tumor-speciﬁc HLA to the FACS buffer. HLA-A2+ single cells were sorted into separate wells of 96peptide ligand presentation could also arise as a byproduct, from wells plates containing 100 µl HISCM with 10 µM LY27632 and coated with BME.
 Sorted cells were then covered with 10 µl BME and placed in the incubator at 37 °C.
the rational need to degrade tumor suppressors and proteins LY27632 was added to the HISCM for the ﬁrst week after sorting. Clonal tumor
needed for DNA damage sensing and repair. Evidence supporting organoids were then expanded in HICS minus WNT conditioned medium.
this “Achilles heel” is presented here in the paired wholeproteome and HLA class I peptide ligand analyses from multiple Whole-genome sequencing and somatic analysis of clonal organoid lines.
tumor clones, and is also logically concordant with the need to Organoids were dissociated and DNA was isolated using the QiaSymphony DSP
accumulate chromosomal lesions, which we observed in kar- DNA Mini Kit (Qiagen; 937236). Libraries were prepared using the Illumina
yotypes. Even within the small tumor-speciﬁc ligand repertoire, TruSeq DNA Nano Library Prep Kit (20015964). Paired-end sequencing of the
 organoid lines was performed (2 × 150 bp) on the generated libraries with 30×
and given the normally low abundance of BRCA proteins, we coverage using the Illumina HiSeq X Ten sequencing system at the Hartwig
could still pick up tumor-speciﬁc BRCA peptides consistently Medical Foundation. Somatic mutations were analyzed by the HMF somatic
across all the CRC clones analyzed, suggesting that this is likely mutation workﬂow from https://github.com/hartwigmedical/pipeline which was
reﬂecting an important molecular alteration in CRC. Since sup- installed the pipeline locally using GNU Guix with the recipe from https://github.
 com/UMCUGenetics/guix-additions. Full pipeline description is explained elsepression of DNA damage sensing and repair is a common trait of where58. Details and settings of all the tools can be found at their Github page.
many cancers, we believe the ﬁndings and rationale we distill here Brieﬂy, sequence reads were mapped against human reference genome GRCh37
could also have strong impact on a variety of cancer and a range using Burrows-Wheeler Alignment (BWA-MEM) v0.7.5a. Subsequently, somatic
of immuno-therapeutic routes. For instance, potentially also in single-base substitutions (SBSs) and small insertions and deletions (INDELS) were
 determined by providing the genotype and tumor (or organoid for in vitro anabreast cancer with HER2 ampliﬁcation but rapid turnover of lysis) sequencing data to Strelka v1.0.14 with adjustments as described in58.
HER2 by degradation53, where targeting HLA peptides derived
from HER2 degradation may also be logical.
 Organoid expansion and quantitative proteomics. Normal colon organoids and
 From a therapeutic point-of-view, HLA peptides with high clonal tumor organoid lines were expanded in their respective media to about 5 ×
tumor speciﬁcity and homogenously high tumor-surface loading 108 cells per organoid line. In the last medium change 3 days prior to harvest for
are best candidates for further testing. While intense efforts have peptidome analysis, the clonal tumor organoids lines received standard HISCM.
been channeled into predicting51 and detecting mutated and On the day of harvest, organoids were removed from the 6-well culture plates using
 medium and P1000 pipettes and spun down for 8 min at 500 g with the brakes off.
spliced ligands to boost tumor speciﬁcity19,46,54,55, relatively little Cell pellets were then incubated with Cell Recovery Solution (Roche Diagnostics)
has been studied regarding the presentation heterogeneity for 30 min on ice to remove excess BME. Cells liberated from BME were then
between clonal tumor populations. We believe the latter would be washed three times in excess PBS to remove any residual BME. After the last wash,
a strong determinant of therapeutic efﬁcacy and residual disease, all PBS was removed and the tube opening was quickly dried using a paper towel.
 Cell pellets were snap frozen in dry ice and stored at −80 °C.
drawing upon lessons learned from chemo-resistance. We show Organoids were lysed by gentle vortexing in 8 M Urea in 50 mM ammonium
here that by using single-cell ampliﬁed organoids from the same bicarbonate supplemented with 50 µg/ml DNAse I (Sigma-Aldrich), 50 µg/ml
patient, that clone-speciﬁc ligandome signatures exist, and RNAse A (Sigma-Aldrich) and 1× complete EDTA-free protease inhibitor cocktail
quantitative variations in clonal presentation are prevalent. In this (Roche Diagnostics). Subsequently, the lysate was cleared by centrifugation for 1 h
 at 18,000 g at 15 °C. Protein concentration was determined with the Bradford assay
respect, immunization with multiple peptides highly conserved in (Bio-Rad). For each sample, 20 µg of total protein was reduced, alkylated, and
presentation, for instance BRCA peptides, may minimize the risk digested sequentially with Lys-C (1:100) and trypsin (1:75). For high-pH reversedof immune escape. phase fractionation, peptide digests were loaded on C18 STAGE-tips in 200 mM

ammonium formate at pH 10 and eluted into 5 fractions with 11–80% acetonitrile. Reporting summary. Further information on research design is available in the Nature
All samples were dried by vacuum centrifugation and reconstituted in 10% formic Research Reporting Summary linked to this article.
acid prior to LC-MS/MS analyses. Per fraction, three technical replicates were
measured by LC-MS/MS.
